| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criterion 6. See AWMSG criteria for appraising a medicine for information. |
|
Medicine details |
|
| Medicine name | formoterol / glycopyrronium bromide / budesonide (Trixeo Aerosphere®) |
| Formulation | 5 micrograms / 7.2 micrograms / 160 micrograms inhalation powder |
| Reference number | 4797 |
| Indication | Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long‑acting beta2‑agonist or combination of a long-acting beta2‑agonist and a long‑acting muscarinic antagonist |
| Company | AstraZeneca UK Ltd |
| BNF chapter | Respiratory system |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 16/11/2020 |